Skip to content Skip to sidebar Skip to footer

US stocks ripped higher on Thursday, capping April with a powerful relief rally that delivered the strongest monthly performance for equities since 2020, as investors cheered resilient growth data, a calmer Treasury market, and Big Tech earnings that were good enough to keep the bull narrative intact. The move came against a backdrop of moderating but still solid GDP growth, sticky services inflation, and a Federal Reserve that has paused further hikes but remains highly data‑dependent, keeping every major macro release market‑moving.

Indexes and sector moves

  • The Dow Jones Industrial Average surged roughly 790 points to close at 49,652.14, putting the blue‑chip gauge on pace for one of its best single sessions of the year and sealing a blockbuster month for cyclicals tied to the US growth story. Today’s move was powered in part by Caterpillar’s (CAT, $890.11, +9.88%) Q1 earnings beat.
  • The S&P 500 notched fresh intraday and closing record highs at 7,209.01, extending this week’s rebound and marking its strongest month since the early post‑pandemic recovery phase in 2020.
  • The Nasdaq Composite also closed at a record at 24,892.31, even as some of the “Magnificent Seven” traded mixed, underscoring how broadening participation beyond mega‑cap tech has been crucial to April’s upside follow‑through.
  • Under the surface, cyclical sectors such as industrials and financials outperformed, while some mega‑cap growth names lagged after a volatile earnings stretch for Alphabet (GOOG, $381.94, +9.97%), Amazon, Microsoft, and Meta.
  • The small caps on the Russell 2000 closed at 2,799.91, +2.21% and is now up +12.81% YTD.

A simple way to frame today: the tape looked less like a narrow AI melt‑up and more like an old‑fashioned “growth is fine, rates are stable, risk back on” session, which is exactly what you want to see if this bull is going to persist.

Macroeconomic backdrop

  • GDP data this week showed the US economy continuing to expand at a solid clip, supporting the soft‑landing narrative and helping investors look through recent volatility in oil and geopolitics.
  • The Federal Reserve held its policy rate in a 3.5%–3.75% range at its latest meeting, in a surprisingly divided 8‑4 decision, reinforcing the idea that the bar for further hikes is high even as officials resist declaring victory on inflation.
  • Fed officials have signaled that future moves will depend heavily on the trajectory of inflation and labor data, leaving the timing of the first cut uncertain and keeping macro prints like PCE, CPI, and payrolls squarely in focus for May.
  • Earlier in the week, markets had to digest rising crude oil prices ($105.55/bbl) and heightened Middle East tensions, but today’s rally suggested investors are increasingly confident that earnings and domestic demand can offset those external shocks—for now.

Put together, the macro mix remains imperfect but investable: growth is slowing from peak levels but not rolling over, inflation is frustrating but no longer accelerating, and monetary policy has shifted from blunt‑force hikes to a more surgical, meeting‑by‑meeting stance.

Earnings and the ‘Mag 7’

  • This week’s flurry of Big Tech earnings has been a key driver of intraday swings, with Microsoft and Alphabet posting strong cloud results, while Meta and Amazon sparked more nuanced reactions around spending, margins, and AI capex.
  • Microsoft beat expectations on the back of ~40% Azure growth, reinforcing the market’s conviction that enterprise AI and cloud remain secular tailwinds even as overall IT budgets normalize.
  • Alphabet’s quarter featured roughly 60%+ growth in cloud revenue, pushing that business above a $20 billion quarterly run‑rate and helping offset investor nerves about ad cyclicality.
  • Meta sold off after guiding 2026 capex sharply higher into the $125–145 billion range, feeding the debate over whether AI infrastructure build‑out is an investment opportunity or an over‑build risk at this stage of the cycle.

For now, the scoreboard favors the bulls: earnings breadth across the S&P 500 remains better than feared, with more than 80% of early reporters beating estimates and aggregate profit growth tracking in the mid‑teens. That backdrop makes it easier for equities to digest a Fed on hold and yields that are no longer collapsing.

Positioning into May

  • With April on track to be the best month for US stocks since 2020, positioning has shifted from underweight to closer to neutral, and the buy‑the‑dip impulse is clearly back in play for many discretionary managers.investopedia+2
  • Key risk catalysts into May include the next wave of macro data (jobs, inflation, and consumer spending), any incremental guidance revisions from AI and cloud leaders, and ongoing geopolitical developments that could spill into energy and FX.team.monetagroup+2
  • From a top‑down lens, investors are watching whether breadth can continue to improve and whether small caps and international equities can finally join US large caps in a sustained way, or if leadership quickly snaps back to a narrow AI‑mega‑cap cohort.heygotrade+1

VP Watchlist Updates

Below is an update‑style snapshot on the VP Watchlist names for the week, focused on recent catalysts, positioning, and narrative rather than precise price moves.

FMC Corporation (NYSE:FMC, $15.38, +4.98%)

FMC Corporation (NYSE:FMC) reported (April 29) first quarter 2026 results above guidance with Adjusted EBITDA above high end of range, reaffirms full-year outlook. Their first quarter 2026 revenue of $759 million, down 4 percent versus first quarter 2025. First quarter 2026 revenue, excluding India, was $762 million, down 4 percent versus first quarter 2025, which included India. On a GAAP basis, the company reported a loss of $2.25 per diluted share in the first quarter, a decrease of $2.13 versus first quarter 2025. First quarter adjusted loss per diluted share of $0.23 was down 41 cents versus first quarter 2025. FMC Corporation also announced today that its board of directors declared a regular quarterly dividend of 8 cents per share, payable on July 16, 2026, to shareholders of record as of the close of business on June 30, 2026.

Eupraxia Pharmaceuticals (EPRX, $7.80, +6.27%)

Eupraxia Pharmaceuticals Inc. (EPRX) is a clinical-stage biotechnology company. It uses its proprietary Diffusphere™ technology to support local, controlled drug delivery. The platform targets medical conditions with significant unmet needs.

On April 21, the company announced 36-week tissue health and symptom data. The results came from patients in the highest-dose cohort of its ongoing RESOLVE trial. This Phase 1b/2a study evaluates EP-104GI as a treatment for eosinophilic esophagitis (EoE).

Eupraxia CEO Dr. James A. Helliwell highlighted the sustained response observed at 36 weeks:

“We are very pleased with the robust and sustained response in both tissue health and symptom data in the highest dose cohort at 36 weeks. This data is consistent with the compelling results we observed at earlier timepoints at this dose level, highlighting the potential to achieve both strong and durable responses after a single administration of EP-104GI. We are also reassured by the excellent safety outcomes across all doses in the trial as we continue to observe no indication of drug related SAEs or spikes in glucose or cortisol. We look forward to the results of the placebo-controlled Phase 2b portion of the study where the same dose is being further evaluated.”

The company also reported no indication of drug-related serious adverse events (SAEs). It observed no spikes in glucose or cortisol across the trial doses. These findings remain encouraging, although further clinical evaluation is needed.

The next important milestone is the placebo-controlled Phase 2b portion of the RESOLVE study. Researchers will evaluate the same dose to gather additional evidence on EP-104GI.

CEO Webinar Highlights Eupraxia’s EoE Strategy

Eupraxia recently co-hosted a CEO presentation and Q&A webinar with Tribe Public. The event took place on Wednesday, April 1. It was titled “Turning EoE Into a Once-a-Year Appointment.”

The webinar featured Dr. James A. Helliwell, Co-founder and CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX). He discussed the company’s precision drug-delivery platform and its approach to treating EoE. The presentation also covered broader pipeline priorities. A focused 5–10-minute Q&A followed the discussion.

Watch the webinar: Turning EoE Into a Once-a-Year Appointment

Modular Medical (MODD, $4.34, +4.08%)

CEO to Discuss Manufacturing Plans and Growth Strategy

Modular Medical, Inc. (NASDAQ: MODD) develops patient-focused insulin delivery solutions. CEO Jeb Besser will present at an upcoming Tribe Public webinar. The event is titled “From FDA Wins to Scaling Manufacturing – What Investors Should Watch.”

The webinar will begin at 8 a.m. Pacific / 11 a.m. Eastern on Friday, May 1, 2026. Investors can attend the complimentary event by registering at MODD-May-Watch.TribePublic.com.

Modular Medical Announces $3.4 Million Offering

On April 19, Modular Medical announced a registered direct offering of 750,000 common shares. The company priced each share at $4.50.

The offering could generate approximately $3.4 million in gross proceeds. Modular Medical will use the funds after deducting placement agent fees and other offering expenses. The company expected to close the offering around April 21, 2026, subject to customary closing conditions.

FDA Clears Modular Medical’s Pivot Insulin Patch Pump

Modular Medical recently secured FDA 510(k) clearance for its Pivot tubeless insulin patch pump. This milestone moves the device closer to commercial sales in the United States. It also gives the company a clearer path toward entering the insulin pump market.

The FDA cleared Pivot as a removable insulin delivery system for adults with diabetes. The device features a simplified, two-part patch pump design. It includes a removable 3-milliliter reservoir and does not require battery recharging. Users can also deliver bolus doses without a dedicated controller.

Modular Medical designed Pivot for people who find traditional insulin pumps too complex, bulky, or expensive. The company aims to offer a simpler alternative to multiple daily insulin injections.

The global insulin pump market has an estimated value of approximately $8 billion. FDA clearance gives Modular Medical an opportunity to compete in this market. However, commercial success will depend on manufacturing scale, product adoption, and market execution.

The InterGroup Corporation (INTG, $41.69)

  • InterGroup Corporation delivered (Feb. 17) a notably stronger quarter, highlighted by a 20% jump in total revenue to $17.3 million and a 27% surge in hotel revenue as renovated rooms returned to service and travel demand improved. The company swung from a prior-year net loss to $1.0 million in net income, with operating income more than doubling to $2.0 million, underscoring better cost control and improved operating efficiency. Management further enhanced liquidity and sharpened strategic focus by selling a non-core 12‑unit Los Angeles multifamily property, generating a meaningful gain and additional working capital while maintaining stable performance across its real estate portfolio.

Volato Group (SOAR) and M2i Global (MTWO): Merger Developments and Business Updates

Volato Group, Inc. (NYSE American: SOAR) and M2i Global, Inc. (OTCQB: MTWO) announced several business developments in early 2026. Their proposed merger aimed to combine critical-minerals operations with technology and software capabilities.

The companies also highlighted developments in aviation technology and mineral supply chains. However, the proposed merger was later terminated in June 2026. This update is important when assessing the companies’ original announcements.

M2i Global Preferred Stockholder Approves Proposed Merger

On April 28, 2026, M2i Global announced a key approval milestone. The sole holder of its Series A Super Voting Preferred Stock voted in favor of the proposed merger with Volato.

Each preferred share carried 10,000 votes. Under the merger agreement, M2i Global was expected to become a wholly owned subsidiary of Volato.

The proposed transaction also included a company name change. Volato planned to adopt the M2i Global name after closing.

Volato Schedules Shareholder Meeting

On April 16, 2026, Volato announced a special shareholder meeting. The meeting was scheduled for May 7, 2026, to consider the proposed merger.

Shareholders recorded as of April 17, 2026, were eligible to vote. At the time, Volato expected the transaction to close shortly after the meeting. Completion remained subject to shareholder approval and other customary conditions.

The proposed ownership structure allocated approximately 85% of the combined company to existing M2i Global shareholders. Volato shareholders were expected to own the remaining 15%. These estimates excluded warrants.

The planned combination aimed to bring together different business capabilities. M2i Global contributed expertise in mining, refining and critical-mineral recycling. Volato brought software, data systems and operational capabilities.

The companies intended to build a technology-enabled platform. Its main focus was strengthening critical-minerals supply chains.

SEC Clears Registration Statement for the Proposed Merger

On April 13, 2026, Volato and M2i Global announced that the SEC had declared their Form S-4 registration statement effective.

This milestone advanced the proposed transaction toward shareholder approval. Volato also planned to distribute the definitive proxy statement and prospectus.

The shareholder meeting was scheduled for May 7. However, the merger did not ultimately proceed.

Volato Terminates the M2i Global Merger Agreement

On June 4, 2026, Volato delivered written notice terminating the merger agreement. The company also abandoned the proposed transaction.

The merger had not been completed by its extended deadline of March 31, 2026. Volato later confirmed that the agreement had been terminated without a termination fee or penalty.

On June 15, 2026, Volato requested withdrawal of the related SEC registration statement. The company stated that it no longer planned to complete the transaction.

This development changed the outlook for both companies. The previously announced ownership structure and planned name change should not be presented as completed events.

flyExclusive Advances Its Aviation Technology

On March 25, 2026, flyExclusive (NYSE American: FLYX) announced two technology developments. The company filed a utility patent application for an aircraft scheduling optimization system. It also announced plans to offer its Contrails Flight Management System to other Part 135 operators in Q2 2026.

The announcements coincided with the NBAA Schedulers & Dispatchers Conference in Cleveland. Contrails was developed using flyExclusive’s operational experience and technology.

The company said it received nearly 300 trip requests per day that it could not fulfill due to limited aircraft availability. It believes Contrails could improve scheduling and coordination across operators.

The platform could also create additional revenue opportunities. Wider adoption may help flyExclusive serve more operators and improve aircraft utilization.

Volato Announces $1.3 Million Legacy IP Asset Sale

On March 10, 2026, Volato announced an amendment to its Aircraft Management Services Agreement with flyExclusive.

The agreement covered the sale of certain legacy intellectual property assets. The transaction was valued at approximately $1.3 million. Payment was expected in flyExclusive Class A common stock, subject to customary conditions.

These assets came from Volato’s earlier technology initiatives. They were not part of its current operating platforms.

Volato said it was reviewing opportunities to streamline its assets. The company also planned to focus resources on its core software platforms and strategic priorities.

Titanium X Initiates First Titanium Ore Shipment

On February 4, 2026, M2i Global and Volato announced a milestone involving Titanium X. The company had initiated its first titanium ore shipment from Western Australia to the United States.

The shipment included samples from mineral sands and hard rock sources. Selected academic institutions and a U.S. defense industry company were expected to receive the material.

These organizations would evaluate the samples and identify suitable refining processes. The initiative supports Titanium X’s efforts to develop critical-mineral supply chains.

What Investors Should Watch

The termination of the proposed merger remains a major development for Volato and M2i Global. Investors should distinguish the original merger plans from the companies’ subsequent business activities.

Other developments remain relevant. These include flyExclusive’s Contrails platform, its aircraft scheduling technology and Titanium X’s critical-minerals activities.

The original merger aimed to create a broader business platform. However, that combination did not take place. Future progress will depend on each company’s independent business strategy, execution and commercial results.

NVIDIA (NVDA, $199.57) & Nokia (NOK, $12.91, +3.61%)

  • Nokia just served Wall Street a quietly confident Q1, the kind of quarter that doesn’t light up the meme feeds but does make long-only portfolio managers reach for their notebooks instead of the antacids.
  • In an AI market obsessed with GPUs and stardust, Nokia (NOK) is quietly reminding investors that none of this magic moves without serious plumbing. While Nvidia (NVDA) prepares to headline its GTC 2026 “Woodstock of AI” showcase, the chip giant has already written a very real check to Nokia, committing a $1 billion investment to help rewire the world’s networks for 5G‑Advanced, 6G, and AI‑native workloads. The message is simple enough: GPUs may be the new rock stars, but networking is the stadium.
  • Nvidia delivered strong fourth-quarter results recently, posting revenue of $68.1 billion, well above analyst expectations. Looking ahead, the company projects $7.8 billion in revenue for the first quarter of 2026, reflecting continued robust demand for its AI chips even amid broader market headwinds.
  • NVIDIA and Nebius Group N.V. (NASDAQ: NBIS) (March 11) announced a strategic partnership to develop and deploy the next generation of hyperscale cloud for the AI market, from AI natives to enterprises. NVIDIA will invest $2 billion in Nebius.

McDonald’s (MCD, $293.59, +1.21%)

  • Morgan Stanley (April 21) has adjusted its price target on McDonald’s (MCD) to $334, maintaining an Equal Weight stance on the stock . The firm’s analyst highlighted consumer strength heading into first-quarter results, noting that earnings quality will likely vary across the restaurant and food distribution landscape . While some operators may face headwinds, the underlying consumer backdrop remains robust, which could support McDonald’s performance as one of the industry’s quality players positioned to navigate the current environment .

Tesla (TSLA, $381.63, +2.37%)

Reportedly, Tesla recently and unexpectedly swung to positive free cash flow in the first quarter, a neat trick for a company many on Wall Street still expected to be busily torching cash. The electric-vehicle maker has yet to fully open the spending spigots on artificial intelligence and added manufacturing capacity, suggesting the real splurge is still to come.

Reportedly, Ross Gerber of Gerber Kawasaki believes that combining Tesla and SpaceX could create a Berkshire Hathaway–style powerhouse focused on artificial intelligence.

Serina Therapeutics (NYSE: SER, $1.82)

Serina Therapeutics (NYSE: SER) (www.serinatx.com) seems to have have just traded itself into Wall Street’s good graces, pairing fresh capital with a late-session pop that suggests investors are finally starting to connect the dots between polymer chemistry and portfolio returns. In Huntsville, Alabama, Serina Therapeutics announced definitive agreements for a private placement of common stock and pre-funded warrants that could bring in up to 30 million dollars in gross proceeds. The first 15 million dollar tranche is expected to close on March 20, 2026, with a second tranche of up to 15 million dollars anticipated by April 30, 2026, subject to customary closing conditions.

What makes the deal stand out in a biotech tape crowded with discounts is the pricing: the securities are being sold at about 2.25 dollars per share, a roughly 68 percent premium to Serina’s March 17 closing price, signaling that insiders are willing to pay up for exposure to the company’s clinical agenda. The financing also adds board-level heft, with director Greg Bailey, M.D., stepping into a Co-Chairman role as he leads the investment, a move that effectively puts the capital and the governance on the same optimistic page. Learn more here.

Intel (INTC, $94.48)

FPT and Intel, a global leader in semiconductor and AI technologies, recently announced a strategic relationship to deliver an end-to-end AI-driven factory optimization solution. Powered by AI, simulation, and digital manufacturing technologies, the collaboration aims to reduce bottlenecks, accelerate decision-making and improve downtime recovery, facilitating the sector’s transition towards AI-driven, autonomous operations.

Walmart (WMT, $131.93, +3.06%)

Walmart’s (WMT) latest move into digital health reads less like a retail side-hustle and more like an opening bell in the next leg of the GLP‑1 trade, with syringes, smartphones, and stock tickers all lining up on aisle 7. 

The Sources

Disclosure: This article is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any security. Market data are subject to revision, and investors should conduct independent due diligence before making investment decisions. Investments may involve substantial risk, including the potential loss of the entire investment. Investors should conduct independent due diligence and consider their individual objectives and risk tolerance. See The Complete Disclosure via this link & at the top of the page.